Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

Stage IV Colorectal Cancer AJCC v8 Clinical Trial

Official title:

Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients With Metastatic GastroIntestinal Malignancies Progressing on Immune Therapy (ARM-GI)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04221893
• Other study ID #: 19721
• Secondary ID: NCI-2019-08355
• Status: Recruiting
• Phase: N/A
• Start date: August 7, 2020
• Est. completion date: November 30, 2026

Study information

• Verified date: November 2023
• Source: University of California, San Francisco
• Contact: Hewitt Chang
• Phone: (415) 514-1571
• Email: Hewitt.Chang[@]ucsf.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. This trial is being done to determine if giving radiation therapy to patients who are being treated with immunotherapy and whose cancers are progressing (getting worse) can slow or stop the growth of their cancers. It may also help researchers determine if giving radiation therapy to one tumor can stimulate the immune system to attack other tumors in the body that are not targeted by the radiation therapy.

Description:

PRIMARY OBJECTIVE:

I. To determine whether radiation therapy can convert overall response rates from progressive disease to stable or responsive disease as measured by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1.

SECONDARY OBJECTIVES:

I. To define overall response rate by immune-Modified Response Evaluation Criteria in Solid Tumors (iRECIST) criteria.

II. To determine time to progression. III. To determine overall survival. IV. To determine local control in radiated lesion(s). V. To characterize the effect of distant radiation on unirradiated target lesions.

VI. To describe the incidence of new metastatic lesions. VII. To determine treatment safety by Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0.

VIII. To describe time to new systemic therapy.

EXPLORATORY OBJECTIVES:

I. To define radiation-induced effects on circulating immune cells. II. To describe remodeling of the circulating T cell repertoire by deep sequencing of variable, diversity and joining (VDJ) regions of T cell receptors (TCRs).

III. To describe changes in circulating tumor deoxyribonucleic acid (DNA) (ctDNA).

OUTLINE:

Patients undergo radiation therapy for a total of 5 treatments over 5-9 calendar days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 14 day, 6 months, and then up to 36 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 28
• Est. completion date: November 30, 2026
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients must have a histologically, cytologically, or radiographically confirmed metastatic gastrointestinal (GI) malignancy (esophageal, gastroesophageal, gastric, small intestine, hepatocellular, pancreaticobiliary, colorectal, or anal cancer).

2. Patients must be receiving immunotherapy (checkpoint inhibitor or CTLA4 inhibitor) with overall response of progressive disease by RECIST criteria.

3. Patients must have at least two metastases which are individually progressing as per RECIST criteria, one of which can be safely unirradiated as adjudicated by the treating radiation oncologist (e.g. lesions for which small increases in dimensions are unlikely to precipitate significant symptoms).

4. Patients must have 1-5 sites of disease meeting standard-of-care indications for palliative radiation therapy as adjudicated by the treating radiation oncologist. For example:

• Symptomatic disease causing pain, bleeding, dyspnea, dysphagia, or nausea

• At-risk for neurologic, respiratory, cardiovascular, gastrointestinal, musculoskeletal, or hepatobiliary compromise

5. Evaluation by a radiation oncologist within 28 days of study registration.

6. Must have adequate organ function to administer radiation therapy and immunotherapy as per standard of care.

7. Age >= 18 years.

8. Life expectancy exceeding 6 months.

9. Eastern Cooperative Oncology Group (ECOG) 0-2 or Karnofsky performance status >= 50.

10. Radiation therapy is known to be teratogenic and therefore women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of radiation therapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for 3 months after completion of radiation therapy. Contraception requirements during the follow-up period of 6 months will be according to standard of care for immunotherapy administration.

a. If a woman is of child-bearing potential, a negative pregnancy test within 28 days prior to study enrollment is required.

11. Ability to understand a written informed consent document, and the willingness to sign it.

Exclusion Criteria:

1. Enrollment on immunotherapy clinical trial for which radiation therapy is not permitted.

2. Administration of radiation therapy within 4 weeks prior to study enrollment.

3. Treatment with systemic corticosteroids or other immunosuppressive medications which would significantly diminish the effect of immunotherapy as judged by the treating physician.

4. Radiation therapy is contraindicated as adjudicated by the radiation oncologist.

Related Conditions & MeSH terms

• Adenocarcinoma
• Anus Neoplasms
• Carcinoma
• Carcinoma, Hepatocellular
• Carcinoma, Squamous Cell
• Colorectal Neoplasms
• Digestive System Neoplasms
• Esophageal Neoplasms
• Esophageal Squamous Cell Carcinoma
• Gastrointestinal Neoplasms
• Metastatic Anal Canal Carcinoma
• Metastatic Colorectal Carcinoma
• Metastatic Esophageal Carcinoma
• Metastatic Gastric Carcinoma
• Metastatic Gastroesophageal Junction Adenocarcinoma
• Metastatic Hepatocellular Carcinoma
• Metastatic Malignant Digestive System Neoplasm
• Metastatic Small Intestinal Carcinoma
• Pancreatobiliary Carcinoma
• Pathologic Stage IV Gastric Cancer AJCC v8
• Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8
• Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
• Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
• Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
• Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
• Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
• Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8
• Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
• Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8
• Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
• Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
• Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8
• Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8
• Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
• Stage IV Adenocarcinoma of the Gastroesophageal Junction
• Stage IV Anal Cancer AJCC v8
• Stage IV Colorectal Cancer AJCC v8
• Stage IV Esophageal Adenocarcinoma
• Stage IV Esophageal Squamous Cell Carcinoma
• Stage IV Gastric Cancer
• Stage IV Hepatocellular Carcinoma AJCC v8
• Stage IVA Adenocarcinoma of the Gastroesophageal Junction
• Stage IVA Colorectal Cancer AJCC v8
• Stage IVA Esophageal Adenocarcinoma
• Stage IVA Esophageal Squamous Cell Carcinoma
• Stage IVA Gastric Cancer
• Stage IVA Hepatocellular Carcinoma AJCC v8
• Stage IVB Colorectal Cancer AJCC v8
• Stage IVB Esophageal Adenocarcinoma
• Stage IVB Esophageal Squamous Cell Carcinoma
• Stage IVB Gastric Cancer
• Stage IVB Gastroesophageal Junction Adenocarcinoma
• Stage IVB Hepatocellular Carcinoma AJCC v8
• Stage IVC Colorectal Cancer AJCC v8
• Stomach Neoplasms

Intervention

Radiation:
• Radiation Therapy (RT)
Undergo radiation therapy

Locations

Country	Name	City	State
United States	University of California, San Francisco	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, San Francisco	Varian Medical Systems

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall response rate (ORR)	Proportion of patients who achieve as their best overall response according to Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1 criteria: Stable disease (SD), partial response (PR), confirmed Complete Response (CR), or progressive disease (PD). Corresponding exact confidence intervals will be reported for the entire cohort and stratified by histologic subtype, programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) status, microsatellite instability (MSI), and organs treated if sample size allows. Patients with unevaluable or unknown response status will be considered nonresponders.	Up to 8 weeks
Secondary	ORR by immune-Modified Response Evaluation Criteria in Solid Tumors (iRECIST)	Will be determined by immune-Modified Response Evaluation Criteria in Solid Tumors (iRECIST). Immune Complete Response (iCR), Partial Response (iPR), or Stable Disease (iSD) per definitions of CR, PR, and SD, but occurring after initial immune unconfirmed progressive disease (iUPD). The same definition will be used for per lesion analysis. PD will be designated for all patients with PD determination by RECIST v1.1 or immune-confirmed progressive disease (iCPD) by iRECIST. Unconfirmed response for all patients designated as iUPD. Will be reported as proportion of response and corresponding exact confidence intervals. Patients with unevaluable or unknown response status will be considered nonresponders.	Up to 8 weeks
Secondary	Progression free survival (PFS)	PFS is defined as the duration of time from start of radiation treatment to time of progression or death a proportion with exact confidence intervals and will be reported for the entire cohort and stratified by histologic subtype, PD1/PDL1 status, MSI, and organs treated if sample size allows. Time to local progression will be described using the cumulative incidence method and comparisons between strata via Gray's test, if sample size allows; Otherwise, Kaplan-Meier methodology will be used and comparisons will be made via log-rank test; and Cox proportional hazards analysis, if possible.	Up to 36 months
Secondary	Overall survival (OS)	OS will be measured from the date of initiation of RT. OS is defined as the time from the date of initiation of RT to the date of death due to any cause. Censoring will be performed using the date of last known contact for those who are alive at the time of analysis. OS will be reported for the entire cohort and stratified by histologic subtype, PD1/PDL1 status, MSI, and organs treated if sample size allows.	Up to 36 months
Secondary	Determine local control in radiated lesion(s)	Local control will be defined as absence of per-lesion PD in an irradiated lesion (as defined above, a 20% increase in the longest diameter since the treatment started or a 5 mm increase over the nadir longest diameter from initiation of radiation therapy to time of progression of radiated lesion(s)	Up to 36 months
Secondary	Tumor measurement change by RECIST or iRECIST	Abscopal response rate is defined as present for all patients for whom an unirradiated target or non-target lesion previously determined to be a progressing lesion is designated as SD, CR/iCR or PR/iPR on per-lesion analysis will be described as a proportion with exact confidence intervals and will be reported for the entire cohort, reported for RECIST and iRECIST definitions, and stratified by histologic subtype, PD1/PDL1 status, MSI, and organs treated if sample size allows	Up to 8 weeks
Secondary	Incidence of New metastatic lesions	From initiation of radiation therapy to first imaging scan after radiation therapy completion, time to new metastatic lesions will be described using the cumulative incidence method and comparisons between strata via Gray's test, if sample size allows; Kaplan-Meier methodology will be used and comparisons will be made via log-rank test; and Cox proportional hazards analysis, if possible.	Up to 8 weeks
Secondary	Frequency of grade 3 or higher adverse events	Common Terminology Criteria for Adverse Events (CTCAE v.5.0) will be used to determine frequency of grade 3 or higher adverse events reported as a proportion with corresponding exact confidence intervals.	Up to 36 months
Secondary	Time to new systemic therapy	Time to new systemic therapy from initiation of radiation therapy to initiation of new systemic therapy will be described using Kaplan-Meier product limit estimators, and Cox proportional hazards analysis, if possible.	Up to 36 months